 Home > Medical News > Medical World News > First break 160 billion! Pharmacy TOP20 reshuffle, Lipitor won the "sales crown" again

First break 160 billion! Pharmacy TOP20 reshuffle, Lipitor won the "sales crown" again

 Last Update: 2023-02-03
 Source: Internet
 Author: User

Tags

ticagrelor brand name

anti jo 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

According to the latest forecast data of Minai.
com, the terminal chemical drug market size of China's urban physical pharmacies in 2022E will exceed 160 billion yuan for the first time, a year-on-year increase of about 4%, and chronic disease drugs will dominate the screen and anti-tumor drugs will rise
.
The ranking of TOP20 products has changed, anti-ED "miracle medicine" ranks first, Hausen's exclusive varieties are on the list, and a new 1 billion single products will be born; 7 TOP20 brands rose by more than 10%, imported original research drugs, and Lipitor won the "sales crown"
again.
The market exceeded 160 billion! Chronic disease drugs dominate the screen, and anti-tumor drugs rise Sales of terminal chemical drugs (including biological drugs) in China's urban physical pharmacies in recent years (: 10,000 yuan) Source: Competition pattern of drug terminals in China's urban physical pharmacies According to data from Minai.
com, the market size of terminal chemical drugs (including biological drugs) in China's urban physical pharmacies has expanded year by year in recent years, and it is expected that 2022E will exceed 160 billion yuan for the first time, a year-on-year increase of about 4%.

2022E Top 10 in the terminal chemical treatment category of China's urban physical pharmacies Source: Competition pattern of drug terminals in China's urban physical pharmacies The 160 billion market covers 14 therapeutic categories, of which digestive system and metabolic drugs, anti-tumor and immunomodulators, and cardiovascular system drugs rank in the top three, accounting for more than 10% of sales, which shows that chronic disease drugs are relatively hot in
Chinese urban physical pharmacies 。 It is worth mentioning that with the approval of more and more anti-tumor innovative drugs, coupled with DTP pharmacies and the "dual-channel" policy, the market share of anti-tumor and immunomodulators in the terminal chemical drugs of physical pharmacies in Chinese cities has increased year by year, from 5.
28% in 2016 to 19.
33%
in 2022E.
From the perspective of manufacturer competition, only 6 of the TOP20 manufacturers are domestic pharmaceutical companies (excluding Sino-foreign joint ventures), and AstraZeneca, Pfizer and Bayer are firmly in the top three, and their sales are expected to exceed 5 billion yuan
in 2022E.
Among domestic pharmaceutical companies, Chia Tai Tianqing Pharmaceutical has not changed its ranking but its market share has increased, while Shiyi Pharmaceutical, Haosen Pharmaceutical, and Baiyunshan Pharmaceutical General Factory have all improved
their ranking.
TOP20 product shuffle! A new 1 billion single product will be born, and Hausen Class 1 new drugs will be on the list 2022E Top 20 products of terminal chemical drugs in China's urban physical pharmacies Source: Minainet Comprehensive Database The total market share of TOP20 products is close to 20%, of which 15 products will have sales of more than 1 billion yuan
.
Anti-ED "miracle drug" - sildenafil citrate tablets continued to lead, with sales of more than 3 billion yuan; Another anti-ED drug, tadalafil tablets, sales will exceed 1 billion yuan
for the first time in 2022E.
Sales of tadalafil tablets in China's urban physical pharmacies in recent years (: million yuan) Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern Tadalafil tablets are selective, reversible inhibitors of specific phosphodiesterase 5 (PDE5) and are indicated for erectile dysfunction
in men.
More than 20 domestic pharmaceutical companies have approved the production of tadalafil tablets, and the sales growth rate of the product in China's urban physical pharmacy terminals has reached double-digit growth in recent years, and it is expected that sales will exceed 1 billion yuan
for the first time in 2022.
Compared with 2021, atorvastatin calcium tablets, clopidogrel hydrogen sulfate tablets, metformin hydrochloride tablets, tadalafil tablets, vitamin AD drops, trastuzumab for injection and other products have improved in the 2022E ranking, of which ametinib mesylate tablets will rank among the top 20
for the first time 。 Sales of ametinib mesylate tablets in China's urban physical pharmacies in recent years (: million yuan) Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern Ametinib mesylate tablets is a domestic class 1 new drug developed by Haosen Pharmaceutical, which was first approved for marketing in March 2020 and is the first domestic third-generation EGFR-TKI
.
According to data from Minai.
com, the sales of ametinib mesylate tablets exceeded 400 million yuan in the first year of its listing in China's urban physical pharmacy terminals, and are expected to exceed 900 million yuan in 2022, and ranked among the top 20
chemical drugs for the first time 。 7 major brands up more than 10%, Lipitor won the "sales crown" again 2022E China Urban Physical Pharmacy Terminal Drug TOP20 Brand Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern Among the TOP20 brands, 6 are exclusive innovative drugs that have not expired the patent period, 9 are unselected varieties (8 are original drugs), and 4 are nutritional supplements
such as vitamins and mineral supplements.
The annual sales of 9 brands will exceed 1 billion yuan, and Pfizer's atorvastatin calcium tablets (Lipitor) and Aonuo (China) Pharmaceutical's calcium and zinc gluconate oral solution will exceed 2 billion yuan
for the first time.
Lipitor was firmly ranked as the top 1 brand from 2015 to 2018, and began to be replaced by other brands in 2019, and is expected to "climb to the top"
again in 2022.
2022E is a brand with a growth rate of more than 10% among the top 20 brands of chemical drugs in China's urban physical pharmacies Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern Seven brands rose by more than 10%, improving their rankings from 2021, with Chinese medicine Star Shark's vitamin D drops ranking among the top 20 brands for the first time, and Haosen Pharmaceutical's ametinib mesylate tablets rising seven places
。 Sales of terminal vitamin D drops (Sinopharm Star Shark) in China's urban physical pharmacies in recent years (: 10,000 yuan) Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern In recent years, Sinopharm Star Shark's vitamin D drops have achieved double-digit sales growth in China's urban physical pharmacy terminals, and are expected to exceed 900 million yuan in 2022, a year-on-year increase of more than 30%.

。 Under the normalization of centralized procurement, most of the original research drugs "abandoned" the in-hospital market and switched to the out-of-hospital market, coupled with the "brand effect" of the original research drugs is difficult to reverse in a short period of time, many original research drugs that have not been selected in centralized procurement still have good sales in physical pharmacies, such as Pfizer's atorvastatin calcium tablets and amlodipine besylate tablets, AstraZeneca's rosuvastatin calcium tablets and metoprolol succinate sustained-release tablets, Bayer's nifedipine controlled-release tablets, etc.
, and it is expected that sales and rankings will improve
in 2022.
Source: Minainet database Note: Minai.
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.